The Technical AnalystExchange: HKSE Industry: Diagnostics & Research
New Horizon Health Price, Forecast, Insider, Ratings, Fundamentals & Signals
-19.75% $14.14
America/New_York / 27 mar 2024 @ 04:08
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 6 448.21 mill |
| EPS: | 0.240 |
| P/E: | 58.92 |
| Earnings Date: | Mar 28, 2024 |
| SharesOutstanding: | 456.03 mill |
| Avg Daily Volume: | 0.722 mill |
| RATING 2024-03-27 |
|---|
| A+ |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Neutral | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | |
| Revenue | n/a | n/a | n/a | n/a | ||
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | n/a | n/a | n/a | n/a | ||
| Asset | n/a | n/a | n/a | n/a | ||
| Debt | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 3.54x |
| Company: PE 58.92 | sector: PE 16.62 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.79x |
| Company: PE 58.92 | industry: PE 32.83 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 13.06 - 15.23 ( +/- 7.67%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.14 (-19.75% ) |
| Volume | 5.34 mill |
| Avg. Vol. | 0.722 mill |
| % of Avg. Vol | 739.67 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 6606.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
6606.HK
New Horizon Health Limited, an investment holding company, engages in the research and development of screening products for colorectal, cervical, and other types of cancer in the People's Republic of China. The company is also involved in the research and development of medical diagnostic technology; provision of technical services, transfers, and consultation; and medical services, as well as financing services; manufacturing and sales of medical and laboratory equipment, and fecal occult blood test kits; and technological import and export activities. The company was founded in 2013 and is headquartered in Hangzhou, China.